Mesoblast Financials

MESO Stock  USD 13.19  0.36  2.66%   
Based on the key indicators related to Mesoblast's liquidity, profitability, solvency, and operating efficiency, Mesoblast is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Mesoblast's Other Current Assets are very stable compared to the past year. As of the 18th of March 2025, Property Plant And Equipment Gross is likely to grow to about 29.1 M, while Total Assets are likely to drop about 583.1 M. Key indicators impacting Mesoblast's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.150.22
Way Down
Slightly volatile
Current Ratio1.291.36
Notably Down
Slightly volatile
The financial analysis of Mesoblast is a critical element in measuring its lifeblood. Investors should not minimize Mesoblast's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(75.2 Million)

  

Mesoblast Stock Summary

Mesoblast competes with Aditxt, Lipocine, Connect Biopharma, Acumen Pharmaceuticals, and Eton Pharmaceuticals. Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia. Mesoblast operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS5907171046
CUSIP590717104 590717401
LocationAustralia
Business Address55 Collins Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.mesoblast.com
Phone61 3 9639 6036
CurrencyUSD - US Dollar

Mesoblast Key Financial Ratios

Mesoblast Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets744.7M662.1M669.4M669.2M769.5M583.1M
Other Current Liab18.7M2.2M5.4M49.7M57.1M60.0M
Net Debt(31.4M)46.9M45.6M56.4M64.8M68.1M
Retained Earnings(647.6M)(738.9M)(820.8M)(908.8M)(817.9M)(777.0M)
Accounts Payable19.6M23.1M20.1M7.1M8.1M15.1M
Cash136.9M60.0M70.9M62.6M71.9M67.2M
Net Receivables4.6M4.4M2.3M21.0M24.1M25.3M
Other Current Assets7.2M5.4M3.7M2.6M2.9M3.9M
Total Liab163.3M165.1M167.6M188.8M217.1M163.4M
Total Current Assets148.2M69.8M81.7M86.5M99.4M116.5M
Intangible Assets446.1M444.2M442.7M441.3M507.5M352.8M
Short Term Debt56.0M8.2M10.0M16.5M19.0M25.5M
Inventory(4.1M)(1.6M)(252K)(4.3M)(3.9M)(3.7M)
Common Stock1.2B1.2B1.2B1.3B1.5B1.0B
Other Liab30.8M19.5M15.0M19.1M17.2M16.3M
Net Tangible Assets(32.3M)851K(81.6M)(75.3M)(86.6M)(91.0M)
Other Assets3.3M1.7M1.9M2.3M2.1M2.0M
Net Invested Capital675.6M593.7M610.6M594.7M683.9M659.7M
Net Working Capital54.0M18.5M39.7M13.2M11.9M11.3M
Long Term Debt41.0M91.6M102.8M100.5M115.6M81.7M
Short Long Term Debt53.2M5.0M6.0M13.9M12.5M21.0M

Mesoblast Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense10.7M16.9M19.4M20.7M23.8M24.9M
Total Revenue7.5M10.2M7.5M5.9M6.8M6.4M
Gross Profit(78.3M)(53.4M)(47.4M)(35.2M)(31.7M)(30.1M)
Operating Income(109.1M)(80.6M)(69.3M)(84.1M)(75.7M)(79.5M)
Ebit(111.9M)(81.0M)(62.7M)(58.0M)(52.2M)(54.8M)
Research Development53.0M32.8M27.2M25.4M29.2M37.9M
Ebitda(107.6M)(76.6M)(58.6M)(56.1M)(50.5M)(53.0M)
Income Before Tax(99.6M)(91.6M)(82.1M)(88.1M)(79.3M)(83.3M)
Net Income(98.8M)(91.3M)(81.9M)(88.0M)(79.2M)(75.2M)
Income Tax Expense(819K)(239K)(212K)191K171.9K180.5K
Cost Of Revenue85.7M63.6M54.9M41.1M47.2M38.1M
Tax Provision(819K)(239K)(212K)(191K)(219.7K)(230.6K)
Net Interest Income(10.7M)(17.3M)(19.3M)(18.8M)(17.0M)(17.8M)
Interest Income22K3K831K1.8M2.1M2.2M

Mesoblast Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash7.6M(76.4M)10.9M(8.4M)(7.5M)(7.1M)
Free Cash Flow(108.3M)(66.0M)(63.6M)(48.8M)(43.9M)(46.1M)
Depreciation4.3M4.4M4.1M4.7M5.4M5.6M
Other Non Cash Items(15.4M)11.0M13.5M31.8M36.6M38.4M
Capital Expenditures1.6M232K314K331K297.9K283.0K
Net Income(98.8M)(91.3M)(81.9M)(88.0M)(79.2M)(75.2M)
End Period Cash Flow136.9M60.4M71.3M63.0M72.4M104.5M
Change To Inventory(12.5M)5.1M(4.8M)398K358.2K376.1K
Investments(1.6M)(232K)(194K)(97K)(111.6K)(117.1K)
Change To Netincome4.6M(3.7M)16.3M17.0M19.5M20.5M
Net Borrowings(1.6M)(2.9M)(6.3M)(2.7M)(2.4M)(2.3M)

Mesoblast Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Mesoblast's current stock value. Our valuation model uses many indicators to compare Mesoblast value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mesoblast competition to find correlations between indicators driving Mesoblast's intrinsic value. More Info.
Mesoblast is considered to be number one stock in return on equity category among its peers. It is regarded second in return on asset category among its peers . At this time, Mesoblast's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mesoblast's earnings, one of the primary drivers of an investment's value.

Mesoblast Systematic Risk

Mesoblast's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mesoblast volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Mesoblast correlated with the market. If Beta is less than 0 Mesoblast generally moves in the opposite direction as compared to the market. If Mesoblast Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mesoblast is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mesoblast is generally in the same direction as the market. If Beta > 1 Mesoblast moves generally in the same direction as, but more than the movement of the benchmark.

Mesoblast Thematic Clasifications

Mesoblast is part of several thematic ideas from Pharmaceutical Products to Cancer Fighters. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Mesoblast Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mesoblast's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Mesoblast growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.37

At this time, Mesoblast's Price Earnings To Growth Ratio is very stable compared to the past year.

Mesoblast March 18, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Mesoblast help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mesoblast. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mesoblast based on widely used predictive technical indicators. In general, we focus on analyzing Mesoblast Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mesoblast's daily price indicators and compare them against related drivers.
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mesoblast. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.06
Quarterly Revenue Growth
(0.41)
Return On Assets
(0.05)
Return On Equity
(0.18)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.